PRIMARY IGA NEPHROPATHY
Clinical trials for PRIMARY IGA NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IGA NEPHROPATHY trials appear
Sign up with your email to follow new studies for PRIMARY IGA NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug YKST02 aims to tame kidney disease in early trial
Disease control Recruiting nowThis early-stage study tests a new drug called YKST02 in 12 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug is safe and tolerable, and to check if it reduces protein in the urine, a sign of kidney damage. Particip…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 16, 2026 23:38 UTC
-
New drug could slow kidney disease in High-Risk patients
Disease control Recruiting nowThis study tests a new medicine, sefaxersen, for people with a kidney disease called IgA nephropathy that is getting worse despite standard care. About 428 adults will receive either the drug or a placebo to see if it can reduce protein in the urine and protect kidney function ov…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New drug aims to slow kidney damage in IgA nephropathy
Disease control Recruiting nowThis study tests an experimental drug called SHR-2173 in 84 adults with primary IgA nephropathy, a kidney disease that can lead to kidney failure. Participants will receive either the drug or a placebo for 48 weeks, and researchers will measure changes in urine protein levels to …
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New kidney drug trial aims to control IgA nephropathy Long-Term
Disease control Recruiting nowThis study tests a new tablet, HSK39297, for long-term safety and effectiveness in people with IgA nephropathy, a kidney disease. About 73 adults who completed a prior study will take the drug daily, with a possible dose increase if needed. The main goal is to check for side effe…
Matched conditions: PRIMARY IGA NEPHROPATHY
Phase: PHASE2 • Sponsor: Haisco Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:09 UTC